22nd Dec 2020 21:21
(Alliance News) - Amgen Inc and AstraZeneca PLC's tezepelumab asthma drug failed to meet its primary endpoint in a phase III trial, the companies said on Tuesday.
The Source trial tested the efficacy of the drug in 150 severe asthma patients who need the use of oral corticosteroids as well as standard of care.
When compared with a placebo, the drug fell short of its primary endpoint of a "statistically significant reduction" in daily oral corticosteroid dose, without a loss of asthma control.
The latest batch of results comes after data from the Navigator Phase 3 trial showed the drug met its primary endpoint and showed a significant reduction in asthma attacks among patients.
Amgen's Executive Vice President of Research & Development said: "The recent results from our NAVIGATOR trial were impressive, both in terms of the overall clinical data and the reduction in exacerbation rate with tezepelumab treatment, and we continue to work with AstraZeneca on planned regulatory filings in 2021. While the SOURCE results were surprising, they provide important insights into the use of oral corticosteroids and the patients who are receiving them, which we look forward to exploring further."
Amgen shares were 2.9% lower at USD220.72 each in New York on Tuesday afternoon. While in London, AstraZeneca shares closed 1.5% lower at 7,328.00 pence.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca